Pharmaceuticals Services Analyst Santangelo, along with a KOL, discuss Bausch Health’s defense of Xifaxan from generic entry into the market on an Analyst/Industry conference call to be held on December 6 at 11 am. Webcast Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BHC:
- Bausch Health call volume above normal and directionally bullish
- Bausch Health wins Bryhali, Duobrii patent infringement case
- Bausch Health wins DUOBRII, BRYHALI patent infringement case
- Salix launches digital initiatives to raise constipation awareness
- Unusually active option classes on open November 30th